Boehringer, Zealand Begin Phase III Program For Obesity Contender Survodutide

Studies Include Cardiovascular Outcomes Trial

The partners revealed Phase III trial details for GLP-1/glucagon agonist survodutide, where the biggest challenge may be overcoming gastrointestinal side effects seen in Phase II.

Nutritionist sitting at her desk
The three-trial Phase III program will begin enrolling patients soon • Source: Shutterstock

Boehringer Ingelheim GmbH and Zealand Pharma A/S have initiated the Phase III program for their dual agonist of the GLP-1 and glucagon receptors, survodutide, in the treatment of obesity, revealing details on 5 October for three clinical trials designed to demonstrate competitive efficacy and tolerability. After Phase II data showed impressive 18.7% weight loss at the highest dose tested, the Phase III program’s biggest challenge may be to overcome adverse events that led to 28.6% of participants discontinuing treatment.

Key Takeaways
  • Boehringer Ingelheim and Zealand Pharma initiated their Phase III program for GLP-1/glucagon receptor agonist survodutide in obesity with two pivotal trials and a cardiovascular outcomes trial.

    ...

BI and Zealand are developing survodutide (BI 456906) for obesity, but not for type 2 diabetes – unlike GLP-1 agonist class leaders semaglutide, which Novo Nordisk A/S markets as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By 

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By 

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.